Artificial intelligence predicts liver cancer response to combination therapy
Part of Cancer, Digestive system clinical trials.
This study uses artificial intelligence to look at your liver cancer's environment and predict how well it might respond to a combination treatment called TACE (which blocks blood flow to the tumor) plus immunotherapy and targeted therapy. It aims to help personalize your care by better understanding your tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with liver cancer (hepatocellular carcinoma) either by biopsy or by clinical criteria.
- You have at least one liver tumor that can be measured on a CT or MRI scan.
- You have not had another type of cancer in the past 5 years (other than liver cancer).
- You do not have a severe allergy to the contrast dye used for imaging or TACE.
- If you are joining the future-looking part, you are planning to start your first treatment with TACE plus immunotherapy and targeted therapy, and you are expected to live more than 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether an artificial intelligence tool can help doctors choose the right dose for treating advanced hepatocellular carcinoma (HCC), a type of liver cancer. It aims to improve safety and effectiveness by matching treatment to you using your liver function, lab results, and treatment course.
This study uses digital scans of your tumor tissue and CT/MRI images to build a computer model that helps predict whether you might need extra treatment (adjuvant therapy) after liver cancer surgery. The goal is to use your own tissue and scan data to personalize follow-up care.
This study uses an artificial intelligence (AI) tool to help doctors choose the best first-line immunotherapy for your liver cancer. It aims to see if the AI's recommendation improves treatment outcomes compared to standard selection.
This study uses artificial intelligence (AI) to analyze your CT or MRI scans and help predict how well immunotherapy might work for your liver cancer. The goal is to find better ways to match you with the right treatment and improve your outcomes.
This trial uses artificial intelligence to help doctors better stage (classify the severity of) and plan treatment for hepatocellular carcinoma, a type of primary liver cancer. Researchers will collect your clinical information and imaging to see if AI can improve decision-making about your care.
This study uses artificial intelligence to look at tumor samples and MRI scans from people with advanced liver cancer to help choose the best treatment. It aims to make treatment more personalized and effective.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.